nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Cholecalciferol—psoriasis	0.0565	0.106	CbGbCtD
Sitaxentan—CYP3A4—Calcitriol—psoriasis	0.053	0.0996	CbGbCtD
Sitaxentan—CYP2C9—Cholecalciferol—psoriasis	0.047	0.0882	CbGbCtD
Sitaxentan—CYP3A4—Methoxsalen—psoriasis	0.0412	0.0774	CbGbCtD
Sitaxentan—CYP2C19—Prednisone—psoriasis	0.0392	0.0736	CbGbCtD
Sitaxentan—CYP2C19—Cyclosporine—psoriasis	0.0371	0.0697	CbGbCtD
Sitaxentan—CYP2C9—Cyclosporine—psoriasis	0.0309	0.058	CbGbCtD
Sitaxentan—CYP3A4—Cholecalciferol—psoriasis	0.0273	0.0513	CbGbCtD
Sitaxentan—CYP2C19—Dexamethasone—psoriasis	0.0245	0.0459	CbGbCtD
Sitaxentan—CYP3A4—Triamcinolone—psoriasis	0.0237	0.0445	CbGbCtD
Sitaxentan—CYP3A4—Mycophenolate mofetil—psoriasis	0.0237	0.0445	CbGbCtD
Sitaxentan—CYP2C9—Dexamethasone—psoriasis	0.0203	0.0382	CbGbCtD
Sitaxentan—CYP3A4—Betamethasone—psoriasis	0.0203	0.0382	CbGbCtD
Sitaxentan—CYP3A4—Prednisolone—psoriasis	0.0201	0.0377	CbGbCtD
Sitaxentan—CYP3A4—Hydrocortisone—psoriasis	0.019	0.0357	CbGbCtD
Sitaxentan—CYP3A4—Prednisone—psoriasis	0.0189	0.0356	CbGbCtD
Sitaxentan—CYP3A4—Cyclosporine—psoriasis	0.018	0.0337	CbGbCtD
Sitaxentan—CYP3A4—Dexamethasone—psoriasis	0.0118	0.0222	CbGbCtD
Sitaxentan—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000665	0.0818	CbGpPWpGaD
Sitaxentan—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000607	0.0746	CbGpPWpGaD
Sitaxentan—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000412	0.0507	CbGpPWpGaD
Sitaxentan—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000376	0.0462	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000299	0.0368	CbGpPWpGaD
Sitaxentan—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000248	0.0305	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL20—psoriasis	0.000232	0.0285	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—HCAR2—psoriasis	0.000228	0.028	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000214	0.0263	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000171	0.021	CbGpPWpGaD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000169	0.0208	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL20—psoriasis	0.000166	0.0204	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—HCAR2—psoriasis	0.000163	0.02	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000156	0.0192	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000155	0.0191	CbGpPWpGaD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000154	0.0189	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—JUN—psoriasis	0.000141	0.0173	CbGpPWpGaD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000139	0.0171	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—HCAR2—psoriasis	0.000129	0.0158	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000127	0.0156	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL20—psoriasis	0.000118	0.0145	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HCAR2—psoriasis	0.000117	0.0144	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000111	0.0137	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000103	0.0127	CbGpPWpGaD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000102	0.0125	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—JUN—psoriasis	0.000101	0.0124	CbGpPWpGaD
Sitaxentan—Asthenia—Mycophenolic acid—psoriasis	9.69e-05	0.000211	CcSEcCtD
Sitaxentan—Infection—Hydrocortisone—psoriasis	9.65e-05	0.00021	CcSEcCtD
Sitaxentan—Insomnia—Mycophenolate mofetil—psoriasis	9.64e-05	0.00021	CcSEcCtD
Sitaxentan—Dyspepsia—Cyclosporine—psoriasis	9.62e-05	0.00021	CcSEcCtD
Sitaxentan—Nausea—Hydroxyurea—psoriasis	9.58e-05	0.000209	CcSEcCtD
Sitaxentan—Nervous system disorder—Hydrocortisone—psoriasis	9.53e-05	0.000207	CcSEcCtD
Sitaxentan—Eye disorder—Prednisone—psoriasis	9.51e-05	0.000207	CcSEcCtD
Sitaxentan—Decreased appetite—Cyclosporine—psoriasis	9.5e-05	0.000207	CcSEcCtD
Sitaxentan—Tachycardia—Hydrocortisone—psoriasis	9.48e-05	0.000206	CcSEcCtD
Sitaxentan—Somnolence—Mycophenolate mofetil—psoriasis	9.48e-05	0.000206	CcSEcCtD
Sitaxentan—Infestation NOS—Methotrexate—psoriasis	9.47e-05	0.000206	CcSEcCtD
Sitaxentan—Infestation—Methotrexate—psoriasis	9.47e-05	0.000206	CcSEcCtD
Sitaxentan—Flushing—Prednisone—psoriasis	9.44e-05	0.000206	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Cyclosporine—psoriasis	9.44e-05	0.000205	CcSEcCtD
Sitaxentan—Skin disorder—Hydrocortisone—psoriasis	9.44e-05	0.000205	CcSEcCtD
Sitaxentan—Ill-defined disorder—Dexamethasone—psoriasis	9.44e-05	0.000205	CcSEcCtD
Sitaxentan—Ill-defined disorder—Betamethasone—psoriasis	9.44e-05	0.000205	CcSEcCtD
Sitaxentan—Discomfort—Triamcinolone—psoriasis	9.43e-05	0.000205	CcSEcCtD
Sitaxentan—Fatigue—Cyclosporine—psoriasis	9.42e-05	0.000205	CcSEcCtD
Sitaxentan—Dyspepsia—Mycophenolate mofetil—psoriasis	9.39e-05	0.000204	CcSEcCtD
Sitaxentan—Pain—Cyclosporine—psoriasis	9.35e-05	0.000204	CcSEcCtD
Sitaxentan—Constipation—Cyclosporine—psoriasis	9.35e-05	0.000204	CcSEcCtD
Sitaxentan—Dry mouth—Triamcinolone—psoriasis	9.33e-05	0.000203	CcSEcCtD
Sitaxentan—Renal failure—Methotrexate—psoriasis	9.31e-05	0.000203	CcSEcCtD
Sitaxentan—Decreased appetite—Mycophenolate mofetil—psoriasis	9.27e-05	0.000202	CcSEcCtD
Sitaxentan—Anorexia—Hydrocortisone—psoriasis	9.26e-05	0.000202	CcSEcCtD
Sitaxentan—Diarrhoea—Mycophenolic acid—psoriasis	9.24e-05	0.000201	CcSEcCtD
Sitaxentan—Stomatitis—Methotrexate—psoriasis	9.23e-05	0.000201	CcSEcCtD
Sitaxentan—Angiopathy—Prednisone—psoriasis	9.23e-05	0.000201	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—HCAR2—psoriasis	9.21e-05	0.0113	CbGpPWpGaD
Sitaxentan—Conjunctivitis—Methotrexate—psoriasis	9.21e-05	0.0002	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	9.21e-05	0.0002	CcSEcCtD
Sitaxentan—Immune system disorder—Prednisone—psoriasis	9.19e-05	0.0002	CcSEcCtD
Sitaxentan—Malaise—Dexamethasone—psoriasis	9.17e-05	0.0002	CcSEcCtD
Sitaxentan—Malaise—Betamethasone—psoriasis	9.17e-05	0.0002	CcSEcCtD
Sitaxentan—Oedema—Triamcinolone—psoriasis	9.15e-05	0.000199	CcSEcCtD
Sitaxentan—Vertigo—Dexamethasone—psoriasis	9.14e-05	0.000199	CcSEcCtD
Sitaxentan—Vertigo—Betamethasone—psoriasis	9.14e-05	0.000199	CcSEcCtD
Sitaxentan—Constipation—Mycophenolate mofetil—psoriasis	9.12e-05	0.000199	CcSEcCtD
Sitaxentan—Pain—Mycophenolate mofetil—psoriasis	9.12e-05	0.000199	CcSEcCtD
Sitaxentan—Infection—Triamcinolone—psoriasis	9.09e-05	0.000198	CcSEcCtD
Sitaxentan—Hypotension—Hydrocortisone—psoriasis	9.08e-05	0.000198	CcSEcCtD
Sitaxentan—Haematuria—Methotrexate—psoriasis	9.03e-05	0.000197	CcSEcCtD
Sitaxentan—Feeling abnormal—Cyclosporine—psoriasis	9.01e-05	0.000196	CcSEcCtD
Sitaxentan—Insomnia—Prednisolone—psoriasis	9e-05	0.000196	CcSEcCtD
Sitaxentan—Alopecia—Prednisone—psoriasis	8.99e-05	0.000196	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Methotrexate—psoriasis	8.96e-05	0.000195	CcSEcCtD
Sitaxentan—Dizziness—Mycophenolic acid—psoriasis	8.93e-05	0.000195	CcSEcCtD
Sitaxentan—Epistaxis—Methotrexate—psoriasis	8.93e-05	0.000195	CcSEcCtD
Sitaxentan—Tachycardia—Triamcinolone—psoriasis	8.93e-05	0.000194	CcSEcCtD
Sitaxentan—Mental disorder—Prednisone—psoriasis	8.91e-05	0.000194	CcSEcCtD
Sitaxentan—Malnutrition—Prednisone—psoriasis	8.86e-05	0.000193	CcSEcCtD
Sitaxentan—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.79e-05	0.000191	CcSEcCtD
Sitaxentan—Insomnia—Hydrocortisone—psoriasis	8.79e-05	0.000191	CcSEcCtD
Sitaxentan—Urticaria—Cyclosporine—psoriasis	8.68e-05	0.000189	CcSEcCtD
Sitaxentan—Body temperature increased—Cyclosporine—psoriasis	8.64e-05	0.000188	CcSEcCtD
Sitaxentan—Vomiting—Mycophenolic acid—psoriasis	8.59e-05	0.000187	CcSEcCtD
Sitaxentan—Discomfort—Dexamethasone—psoriasis	8.55e-05	0.000186	CcSEcCtD
Sitaxentan—Discomfort—Betamethasone—psoriasis	8.55e-05	0.000186	CcSEcCtD
Sitaxentan—Dyspepsia—Hydrocortisone—psoriasis	8.55e-05	0.000186	CcSEcCtD
Sitaxentan—Haemoglobin—Methotrexate—psoriasis	8.55e-05	0.000186	CcSEcCtD
Sitaxentan—Rash—Mycophenolic acid—psoriasis	8.52e-05	0.000186	CcSEcCtD
Sitaxentan—Dermatitis—Mycophenolic acid—psoriasis	8.51e-05	0.000185	CcSEcCtD
Sitaxentan—Pain—Prednisolone—psoriasis	8.51e-05	0.000185	CcSEcCtD
Sitaxentan—Haemorrhage—Methotrexate—psoriasis	8.5e-05	0.000185	CcSEcCtD
Sitaxentan—Hepatitis—Methotrexate—psoriasis	8.5e-05	0.000185	CcSEcCtD
Sitaxentan—Urticaria—Mycophenolate mofetil—psoriasis	8.47e-05	0.000184	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CCL20—psoriasis	8.47e-05	0.0104	CbGpPWpGaD
Sitaxentan—Headache—Mycophenolic acid—psoriasis	8.46e-05	0.000184	CcSEcCtD
Sitaxentan—Decreased appetite—Hydrocortisone—psoriasis	8.44e-05	0.000184	CcSEcCtD
Sitaxentan—Body temperature increased—Mycophenolate mofetil—psoriasis	8.43e-05	0.000184	CcSEcCtD
Sitaxentan—Urinary tract disorder—Methotrexate—psoriasis	8.4e-05	0.000183	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.39e-05	0.000183	CcSEcCtD
Sitaxentan—Fatigue—Hydrocortisone—psoriasis	8.37e-05	0.000182	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—HCAR2—psoriasis	8.37e-05	0.0103	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.35e-05	0.0103	CbGpPWpGaD
Sitaxentan—Urethral disorder—Methotrexate—psoriasis	8.33e-05	0.000181	CcSEcCtD
Sitaxentan—Pain—Hydrocortisone—psoriasis	8.31e-05	0.000181	CcSEcCtD
Sitaxentan—Oedema—Betamethasone—psoriasis	8.3e-05	0.000181	CcSEcCtD
Sitaxentan—Oedema—Dexamethasone—psoriasis	8.3e-05	0.000181	CcSEcCtD
Sitaxentan—Insomnia—Triamcinolone—psoriasis	8.27e-05	0.00018	CcSEcCtD
Sitaxentan—Infection—Dexamethasone—psoriasis	8.25e-05	0.00018	CcSEcCtD
Sitaxentan—Infection—Betamethasone—psoriasis	8.25e-05	0.00018	CcSEcCtD
Sitaxentan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	8.24e-05	0.0101	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Prednisone—psoriasis	8.22e-05	0.000179	CcSEcCtD
Sitaxentan—Feeling abnormal—Prednisolone—psoriasis	8.2e-05	0.000178	CcSEcCtD
Sitaxentan—Visual impairment—Methotrexate—psoriasis	8.19e-05	0.000178	CcSEcCtD
Sitaxentan—Anaemia—Prednisone—psoriasis	8.19e-05	0.000178	CcSEcCtD
Sitaxentan—Nervous system disorder—Dexamethasone—psoriasis	8.14e-05	0.000177	CcSEcCtD
Sitaxentan—Nervous system disorder—Betamethasone—psoriasis	8.14e-05	0.000177	CcSEcCtD
Sitaxentan—Agitation—Prednisone—psoriasis	8.14e-05	0.000177	CcSEcCtD
Sitaxentan—Thrombocytopenia—Betamethasone—psoriasis	8.13e-05	0.000177	CcSEcCtD
Sitaxentan—Thrombocytopenia—Dexamethasone—psoriasis	8.13e-05	0.000177	CcSEcCtD
Sitaxentan—Tachycardia—Betamethasone—psoriasis	8.1e-05	0.000176	CcSEcCtD
Sitaxentan—Tachycardia—Dexamethasone—psoriasis	8.1e-05	0.000176	CcSEcCtD
Sitaxentan—Hypersensitivity—Cyclosporine—psoriasis	8.05e-05	0.000175	CcSEcCtD
Sitaxentan—Dyspepsia—Triamcinolone—psoriasis	8.05e-05	0.000175	CcSEcCtD
Sitaxentan—Nausea—Mycophenolic acid—psoriasis	8.03e-05	0.000175	CcSEcCtD
Sitaxentan—Feeling abnormal—Hydrocortisone—psoriasis	8e-05	0.000174	CcSEcCtD
Sitaxentan—Malaise—Prednisone—psoriasis	7.99e-05	0.000174	CcSEcCtD
Sitaxentan—Vertigo—Prednisone—psoriasis	7.96e-05	0.000173	CcSEcCtD
Sitaxentan—Eye disorder—Methotrexate—psoriasis	7.95e-05	0.000173	CcSEcCtD
Sitaxentan—Tinnitus—Methotrexate—psoriasis	7.93e-05	0.000173	CcSEcCtD
Sitaxentan—Anorexia—Dexamethasone—psoriasis	7.91e-05	0.000172	CcSEcCtD
Sitaxentan—Anorexia—Betamethasone—psoriasis	7.91e-05	0.000172	CcSEcCtD
Sitaxentan—Urticaria—Prednisolone—psoriasis	7.9e-05	0.000172	CcSEcCtD
Sitaxentan—Cardiac disorder—Methotrexate—psoriasis	7.89e-05	0.000172	CcSEcCtD
Sitaxentan—Fatigue—Triamcinolone—psoriasis	7.89e-05	0.000172	CcSEcCtD
Sitaxentan—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.86e-05	0.000171	CcSEcCtD
Sitaxentan—Asthenia—Cyclosporine—psoriasis	7.84e-05	0.000171	CcSEcCtD
Sitaxentan—Pain—Triamcinolone—psoriasis	7.82e-05	0.00017	CcSEcCtD
Sitaxentan—Hypotension—Dexamethasone—psoriasis	7.76e-05	0.000169	CcSEcCtD
Sitaxentan—Hypotension—Betamethasone—psoriasis	7.76e-05	0.000169	CcSEcCtD
Sitaxentan—Urticaria—Hydrocortisone—psoriasis	7.72e-05	0.000168	CcSEcCtD
Sitaxentan—Angiopathy—Methotrexate—psoriasis	7.71e-05	0.000168	CcSEcCtD
Sitaxentan—Immune system disorder—Methotrexate—psoriasis	7.68e-05	0.000167	CcSEcCtD
Sitaxentan—Body temperature increased—Hydrocortisone—psoriasis	7.68e-05	0.000167	CcSEcCtD
Sitaxentan—Mediastinal disorder—Methotrexate—psoriasis	7.66e-05	0.000167	CcSEcCtD
Sitaxentan—Asthenia—Mycophenolate mofetil—psoriasis	7.65e-05	0.000167	CcSEcCtD
Sitaxentan—Feeling abnormal—Triamcinolone—psoriasis	7.54e-05	0.000164	CcSEcCtD
Sitaxentan—Alopecia—Methotrexate—psoriasis	7.51e-05	0.000164	CcSEcCtD
Sitaxentan—Insomnia—Dexamethasone—psoriasis	7.51e-05	0.000163	CcSEcCtD
Sitaxentan—Insomnia—Betamethasone—psoriasis	7.51e-05	0.000163	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.49e-05	0.000163	CcSEcCtD
Sitaxentan—Diarrhoea—Cyclosporine—psoriasis	7.48e-05	0.000163	CcSEcCtD
Sitaxentan—Discomfort—Prednisone—psoriasis	7.45e-05	0.000162	CcSEcCtD
Sitaxentan—Mental disorder—Methotrexate—psoriasis	7.45e-05	0.000162	CcSEcCtD
Sitaxentan—Malnutrition—Methotrexate—psoriasis	7.4e-05	0.000161	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP2S1—psoriasis	7.37e-05	0.00906	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Prednisolone—psoriasis	7.33e-05	0.00016	CcSEcCtD
Sitaxentan—Dyspepsia—Betamethasone—psoriasis	7.31e-05	0.000159	CcSEcCtD
Sitaxentan—Dyspepsia—Dexamethasone—psoriasis	7.31e-05	0.000159	CcSEcCtD
Sitaxentan—Diarrhoea—Mycophenolate mofetil—psoriasis	7.3e-05	0.000159	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	7.27e-05	0.00894	CbGpPWpGaD
Sitaxentan—Urticaria—Triamcinolone—psoriasis	7.27e-05	0.000158	CcSEcCtD
Sitaxentan—Body temperature increased—Triamcinolone—psoriasis	7.23e-05	0.000157	CcSEcCtD
Sitaxentan—Dizziness—Cyclosporine—psoriasis	7.23e-05	0.000157	CcSEcCtD
Sitaxentan—Oedema—Prednisone—psoriasis	7.23e-05	0.000157	CcSEcCtD
Sitaxentan—Decreased appetite—Dexamethasone—psoriasis	7.21e-05	0.000157	CcSEcCtD
Sitaxentan—Decreased appetite—Betamethasone—psoriasis	7.21e-05	0.000157	CcSEcCtD
Sitaxentan—Infection—Prednisone—psoriasis	7.18e-05	0.000156	CcSEcCtD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.17e-05	0.00881	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Dexamethasone—psoriasis	7.17e-05	0.000156	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Betamethasone—psoriasis	7.17e-05	0.000156	CcSEcCtD
Sitaxentan—Hypersensitivity—Hydrocortisone—psoriasis	7.16e-05	0.000156	CcSEcCtD
Sitaxentan—Fatigue—Dexamethasone—psoriasis	7.16e-05	0.000156	CcSEcCtD
Sitaxentan—Fatigue—Betamethasone—psoriasis	7.16e-05	0.000156	CcSEcCtD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	7.15e-05	0.00879	CbGpPWpGaD
Sitaxentan—Pain—Dexamethasone—psoriasis	7.1e-05	0.000155	CcSEcCtD
Sitaxentan—Pain—Betamethasone—psoriasis	7.1e-05	0.000155	CcSEcCtD
Sitaxentan—Nervous system disorder—Prednisone—psoriasis	7.09e-05	0.000154	CcSEcCtD
Sitaxentan—Tachycardia—Prednisone—psoriasis	7.05e-05	0.000154	CcSEcCtD
Sitaxentan—Dizziness—Mycophenolate mofetil—psoriasis	7.05e-05	0.000154	CcSEcCtD
Sitaxentan—Skin disorder—Prednisone—psoriasis	7.02e-05	0.000153	CcSEcCtD
Sitaxentan—Asthenia—Hydrocortisone—psoriasis	6.97e-05	0.000152	CcSEcCtD
Sitaxentan—Vomiting—Cyclosporine—psoriasis	6.95e-05	0.000151	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HCAR2—psoriasis	6.9e-05	0.00849	CbGpPWpGaD
Sitaxentan—Rash—Cyclosporine—psoriasis	6.89e-05	0.00015	CcSEcCtD
Sitaxentan—Anorexia—Prednisone—psoriasis	6.89e-05	0.00015	CcSEcCtD
Sitaxentan—Dermatitis—Cyclosporine—psoriasis	6.89e-05	0.00015	CcSEcCtD
Sitaxentan—Ill-defined disorder—Methotrexate—psoriasis	6.87e-05	0.00015	CcSEcCtD
Sitaxentan—Headache—Cyclosporine—psoriasis	6.85e-05	0.000149	CcSEcCtD
Sitaxentan—Anaemia—Methotrexate—psoriasis	6.84e-05	0.000149	CcSEcCtD
Sitaxentan—Feeling abnormal—Betamethasone—psoriasis	6.84e-05	0.000149	CcSEcCtD
Sitaxentan—Feeling abnormal—Dexamethasone—psoriasis	6.84e-05	0.000149	CcSEcCtD
Sitaxentan—Vomiting—Mycophenolate mofetil—psoriasis	6.78e-05	0.000148	CcSEcCtD
Sitaxentan—Hypersensitivity—Triamcinolone—psoriasis	6.74e-05	0.000147	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.72e-05	0.00826	CbGpPWpGaD
Sitaxentan—Rash—Mycophenolate mofetil—psoriasis	6.72e-05	0.000146	CcSEcCtD
Sitaxentan—Dermatitis—Mycophenolate mofetil—psoriasis	6.72e-05	0.000146	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—CCL20—psoriasis	6.69e-05	0.00822	CbGpPWpGaD
Sitaxentan—Headache—Mycophenolate mofetil—psoriasis	6.68e-05	0.000145	CcSEcCtD
Sitaxentan—Malaise—Methotrexate—psoriasis	6.67e-05	0.000145	CcSEcCtD
Sitaxentan—Vertigo—Methotrexate—psoriasis	6.65e-05	0.000145	CcSEcCtD
Sitaxentan—Diarrhoea—Hydrocortisone—psoriasis	6.65e-05	0.000145	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.63e-05	0.00815	CbGpPWpGaD
Sitaxentan—Leukopenia—Methotrexate—psoriasis	6.62e-05	0.000144	CcSEcCtD
Sitaxentan—Urticaria—Dexamethasone—psoriasis	6.59e-05	0.000144	CcSEcCtD
Sitaxentan—Urticaria—Betamethasone—psoriasis	6.59e-05	0.000144	CcSEcCtD
Sitaxentan—Dizziness—Prednisolone—psoriasis	6.58e-05	0.000143	CcSEcCtD
Sitaxentan—Asthenia—Triamcinolone—psoriasis	6.56e-05	0.000143	CcSEcCtD
Sitaxentan—Body temperature increased—Betamethasone—psoriasis	6.56e-05	0.000143	CcSEcCtD
Sitaxentan—Body temperature increased—Dexamethasone—psoriasis	6.56e-05	0.000143	CcSEcCtD
Sitaxentan—Insomnia—Prednisone—psoriasis	6.54e-05	0.000142	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.51e-05	0.008	CbGpPWpGaD
Sitaxentan—Nausea—Cyclosporine—psoriasis	6.49e-05	0.000141	CcSEcCtD
Sitaxentan—Dizziness—Hydrocortisone—psoriasis	6.42e-05	0.00014	CcSEcCtD
Sitaxentan—Dyspepsia—Prednisone—psoriasis	6.36e-05	0.000139	CcSEcCtD
Sitaxentan—Nausea—Mycophenolate mofetil—psoriasis	6.33e-05	0.000138	CcSEcCtD
Sitaxentan—Chest pain—Methotrexate—psoriasis	6.3e-05	0.000137	CcSEcCtD
Sitaxentan—Decreased appetite—Prednisone—psoriasis	6.28e-05	0.000137	CcSEcCtD
Sitaxentan—Rash—Prednisolone—psoriasis	6.27e-05	0.000137	CcSEcCtD
Sitaxentan—Dermatitis—Prednisolone—psoriasis	6.27e-05	0.000136	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.26e-05	0.000136	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL8—psoriasis	6.25e-05	0.00769	CbGpPWpGaD
Sitaxentan—Fatigue—Prednisone—psoriasis	6.23e-05	0.000136	CcSEcCtD
Sitaxentan—Headache—Prednisolone—psoriasis	6.23e-05	0.000136	CcSEcCtD
Sitaxentan—Discomfort—Methotrexate—psoriasis	6.23e-05	0.000136	CcSEcCtD
Sitaxentan—Constipation—Prednisone—psoriasis	6.18e-05	0.000135	CcSEcCtD
Sitaxentan—Vomiting—Hydrocortisone—psoriasis	6.18e-05	0.000135	CcSEcCtD
Sitaxentan—Rash—Hydrocortisone—psoriasis	6.12e-05	0.000133	CcSEcCtD
Sitaxentan—Dermatitis—Hydrocortisone—psoriasis	6.12e-05	0.000133	CcSEcCtD
Sitaxentan—Confusional state—Methotrexate—psoriasis	6.09e-05	0.000133	CcSEcCtD
Sitaxentan—Headache—Hydrocortisone—psoriasis	6.09e-05	0.000133	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CCL20—psoriasis	6.07e-05	0.00746	CbGpPWpGaD
Sitaxentan—Dizziness—Triamcinolone—psoriasis	6.05e-05	0.000132	CcSEcCtD
Sitaxentan—Infection—Methotrexate—psoriasis	6e-05	0.000131	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—TAGAP—psoriasis	5.99e-05	0.00736	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Prednisone—psoriasis	5.96e-05	0.00013	CcSEcCtD
Sitaxentan—Asthenia—Betamethasone—psoriasis	5.95e-05	0.00013	CcSEcCtD
Sitaxentan—Asthenia—Dexamethasone—psoriasis	5.95e-05	0.00013	CcSEcCtD
Sitaxentan—Nervous system disorder—Methotrexate—psoriasis	5.92e-05	0.000129	CcSEcCtD
Sitaxentan—Thrombocytopenia—Methotrexate—psoriasis	5.91e-05	0.000129	CcSEcCtD
Sitaxentan—Nausea—Prednisolone—psoriasis	5.91e-05	0.000129	CcSEcCtD
Sitaxentan—Skin disorder—Methotrexate—psoriasis	5.87e-05	0.000128	CcSEcCtD
Sitaxentan—Vomiting—Triamcinolone—psoriasis	5.82e-05	0.000127	CcSEcCtD
Sitaxentan—Nausea—Hydrocortisone—psoriasis	5.77e-05	0.000126	CcSEcCtD
Sitaxentan—Rash—Triamcinolone—psoriasis	5.77e-05	0.000126	CcSEcCtD
Sitaxentan—Dermatitis—Triamcinolone—psoriasis	5.76e-05	0.000125	CcSEcCtD
Sitaxentan—Anorexia—Methotrexate—psoriasis	5.76e-05	0.000125	CcSEcCtD
Sitaxentan—Urticaria—Prednisone—psoriasis	5.74e-05	0.000125	CcSEcCtD
Sitaxentan—Headache—Triamcinolone—psoriasis	5.73e-05	0.000125	CcSEcCtD
Sitaxentan—Body temperature increased—Prednisone—psoriasis	5.71e-05	0.000124	CcSEcCtD
Sitaxentan—Diarrhoea—Dexamethasone—psoriasis	5.68e-05	0.000124	CcSEcCtD
Sitaxentan—Diarrhoea—Betamethasone—psoriasis	5.68e-05	0.000124	CcSEcCtD
Sitaxentan—Hypotension—Methotrexate—psoriasis	5.64e-05	0.000123	CcSEcCtD
Sitaxentan—Dizziness—Betamethasone—psoriasis	5.49e-05	0.00012	CcSEcCtD
Sitaxentan—Dizziness—Dexamethasone—psoriasis	5.49e-05	0.00012	CcSEcCtD
Sitaxentan—Insomnia—Methotrexate—psoriasis	5.46e-05	0.000119	CcSEcCtD
Sitaxentan—Nausea—Triamcinolone—psoriasis	5.43e-05	0.000118	CcSEcCtD
Sitaxentan—Somnolence—Methotrexate—psoriasis	5.37e-05	0.000117	CcSEcCtD
Sitaxentan—Hypersensitivity—Prednisone—psoriasis	5.32e-05	0.000116	CcSEcCtD
Sitaxentan—Dyspepsia—Methotrexate—psoriasis	5.32e-05	0.000116	CcSEcCtD
Sitaxentan—Vomiting—Dexamethasone—psoriasis	5.28e-05	0.000115	CcSEcCtD
Sitaxentan—Vomiting—Betamethasone—psoriasis	5.28e-05	0.000115	CcSEcCtD
Sitaxentan—Decreased appetite—Methotrexate—psoriasis	5.25e-05	0.000114	CcSEcCtD
Sitaxentan—Rash—Dexamethasone—psoriasis	5.23e-05	0.000114	CcSEcCtD
Sitaxentan—Rash—Betamethasone—psoriasis	5.23e-05	0.000114	CcSEcCtD
Sitaxentan—Dermatitis—Dexamethasone—psoriasis	5.23e-05	0.000114	CcSEcCtD
Sitaxentan—Dermatitis—Betamethasone—psoriasis	5.23e-05	0.000114	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Methotrexate—psoriasis	5.21e-05	0.000114	CcSEcCtD
Sitaxentan—Fatigue—Methotrexate—psoriasis	5.21e-05	0.000113	CcSEcCtD
Sitaxentan—Headache—Dexamethasone—psoriasis	5.2e-05	0.000113	CcSEcCtD
Sitaxentan—Headache—Betamethasone—psoriasis	5.2e-05	0.000113	CcSEcCtD
Sitaxentan—Asthenia—Prednisone—psoriasis	5.19e-05	0.000113	CcSEcCtD
Sitaxentan—Pain—Methotrexate—psoriasis	5.17e-05	0.000112	CcSEcCtD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5e-05	0.00615	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Methotrexate—psoriasis	4.98e-05	0.000108	CcSEcCtD
Sitaxentan—Diarrhoea—Prednisone—psoriasis	4.95e-05	0.000108	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HCAR2—psoriasis	4.94e-05	0.00607	CbGpPWpGaD
Sitaxentan—Nausea—Dexamethasone—psoriasis	4.93e-05	0.000107	CcSEcCtD
Sitaxentan—Nausea—Betamethasone—psoriasis	4.93e-05	0.000107	CcSEcCtD
Sitaxentan—Urticaria—Methotrexate—psoriasis	4.8e-05	0.000104	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCL20—psoriasis	4.78e-05	0.00588	CbGpPWpGaD
Sitaxentan—Dizziness—Prednisone—psoriasis	4.78e-05	0.000104	CcSEcCtD
Sitaxentan—Body temperature increased—Methotrexate—psoriasis	4.77e-05	0.000104	CcSEcCtD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.73e-05	0.00581	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.66e-05	0.00572	CbGpPWpGaD
Sitaxentan—Vomiting—Prednisone—psoriasis	4.6e-05	0.0001	CcSEcCtD
Sitaxentan—Rash—Prednisone—psoriasis	4.56e-05	9.92e-05	CcSEcCtD
Sitaxentan—Dermatitis—Prednisone—psoriasis	4.55e-05	9.91e-05	CcSEcCtD
Sitaxentan—Headache—Prednisone—psoriasis	4.53e-05	9.86e-05	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL8—psoriasis	4.48e-05	0.0055	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Methotrexate—psoriasis	4.45e-05	9.69e-05	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.43e-05	0.00545	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.37e-05	0.00538	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL20—psoriasis	4.35e-05	0.00534	CbGpPWpGaD
Sitaxentan—Asthenia—Methotrexate—psoriasis	4.33e-05	9.44e-05	CcSEcCtD
Sitaxentan—Nausea—Prednisone—psoriasis	4.29e-05	9.35e-05	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TAGAP—psoriasis	4.28e-05	0.00527	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.25e-05	0.00523	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.2e-05	0.00516	CbGpPWpGaD
Sitaxentan—Diarrhoea—Methotrexate—psoriasis	4.13e-05	9e-05	CcSEcCtD
Sitaxentan—Dizziness—Methotrexate—psoriasis	3.99e-05	8.7e-05	CcSEcCtD
Sitaxentan—Vomiting—Methotrexate—psoriasis	3.84e-05	8.36e-05	CcSEcCtD
Sitaxentan—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.83e-05	0.0047	CbGpPWpGaD
Sitaxentan—Rash—Methotrexate—psoriasis	3.81e-05	8.29e-05	CcSEcCtD
Sitaxentan—Dermatitis—Methotrexate—psoriasis	3.81e-05	8.29e-05	CcSEcCtD
Sitaxentan—Headache—Methotrexate—psoriasis	3.78e-05	8.24e-05	CcSEcCtD
Sitaxentan—Nausea—Methotrexate—psoriasis	3.59e-05	7.81e-05	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCL20—psoriasis	3.59e-05	0.00441	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.3e-05	0.00405	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL8—psoriasis	3.19e-05	0.00393	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.18e-05	0.00391	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3e-05	0.00369	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL20—psoriasis	2.57e-05	0.00315	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL8—psoriasis	2.29e-05	0.00281	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.28e-05	0.0028	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SOCS1—psoriasis	1.97e-05	0.00243	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—TYK2—psoriasis	1.88e-05	0.00231	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL8—psoriasis	1.81e-05	0.00222	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL8—psoriasis	1.64e-05	0.00201	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NDUFA5—psoriasis	1.48e-05	0.00182	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—LEP—psoriasis	1.46e-05	0.00179	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—APOE—psoriasis	1.46e-05	0.00179	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SOCS1—psoriasis	1.41e-05	0.00174	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.38e-05	0.0017	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NFKBIA—psoriasis	1.36e-05	0.00167	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NDUFA5—psoriasis	1.35e-05	0.00166	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TYK2—psoriasis	1.35e-05	0.00166	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—psoriasis	1.29e-05	0.00159	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP2S1—psoriasis	1.26e-05	0.00155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.26e-05	0.00155	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—psoriasis	1.17e-05	0.00144	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2S1—psoriasis	1.15e-05	0.00141	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TYK2—psoriasis	1.11e-05	0.00137	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—LEP—psoriasis	1.04e-05	0.00128	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APOE—psoriasis	1.04e-05	0.00128	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NFKBIA—psoriasis	9.72e-06	0.00119	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—psoriasis	9.69e-06	0.00119	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—psoriasis	9.21e-06	0.00113	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—JUN—psoriasis	9e-06	0.00111	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NDUFA5—psoriasis	8.92e-06	0.0011	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NFKB1—psoriasis	8.67e-06	0.00107	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TYK2—psoriasis	7.96e-06	0.000978	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—psoriasis	7.87e-06	0.000967	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—psoriasis	7.79e-06	0.000957	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2S1—psoriasis	7.58e-06	0.000932	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—psoriasis	6.93e-06	0.000852	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.61e-06	0.000812	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—psoriasis	6.59e-06	0.00081	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—JUN—psoriasis	6.44e-06	0.000792	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NFKB1—psoriasis	6.2e-06	0.000762	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CARM1—psoriasis	6.16e-06	0.000757	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.03e-06	0.000741	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—psoriasis	5.94e-06	0.00073	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.76e-06	0.000707	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—psoriasis	5.63e-06	0.000692	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CARM1—psoriasis	5.62e-06	0.00069	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—psoriasis	5.57e-06	0.000685	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—psoriasis	5.44e-06	0.000669	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.25e-06	0.000645	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—psoriasis	4.25e-06	0.000523	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—psoriasis	3.89e-06	0.000479	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CAT—psoriasis	3.79e-06	0.000466	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CARM1—psoriasis	3.7e-06	0.000455	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CAT—psoriasis	3.45e-06	0.000424	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—APOE—psoriasis	2.94e-06	0.000362	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—APOE—psoriasis	2.68e-06	0.00033	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARG—psoriasis	2.56e-06	0.000315	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARG—psoriasis	2.34e-06	0.000287	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CAT—psoriasis	2.28e-06	0.00028	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APOE—psoriasis	1.77e-06	0.000218	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARG—psoriasis	1.54e-06	0.000189	CbGpPWpGaD
